Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 312-321

  Yoshitake, Yoshihiro ^a,b   Fukuma, Daiki ^a   Yuno, Akira ^a   Hirayama, Masatoshi ^a   Nakayama, Hideki ^a   Tanaka, Takuya ^a   Nagata, Masashi ^a,c   Takamune, Yasuo ^a   Kawahara, Kenta ^a   Nakagawa, Yoshihiro ^a   Yoshida, Ryoji ^a   Hirosue, Akiyuki ^a   Ogi, Hidenao ^a   Hiraki, Akimitsu ^a   Jono, Hirofumi ^d   Hamada, Akinobu ^d,e   Yoshida, Koji ^f,g   Nishimura, Yasuharu ^a   Nakamura, Yusuke ^h   Shinohara, Masanori ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Itoh Maxillofacial Hospital   (Japan)

^c Minamata City Hospital and Medical Center   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e Group for Translational Research Support Core   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g Research and Development Division   (Japan)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANCER TESTIS ANTIGEN; CDCA1 ANTIGEN; CISPLATIN; CREATININE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; GIMERACIL; HLA A ANTIGEN; HLA A24 ANTIGEN; IMP3 ANTIGEN; LY6K ANTIGEN; MONTANIDE ISA 51; OTERACIL POTASSIUM; PEPTIDE VACCINE; TEGAFUR; UNCLASSIFIED DRUG; CANCER VACCINE; SUBUNIT VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; MALE; MANDIBLE CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHARYNX CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; PROTHROMBIN TIME; PRURITUS; RASH; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TONGUE CANCER; TREATMENT OUTCOME; VERY ELDERLY; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; VACCINATION;

AGED; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 84921029675     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0202     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Howlader NNA, Krapcho M, Neyman N, et al., editors. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
5. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338: 1798-804.
6. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006;24:2612-7.
7. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007;25:4118-26.
8. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
9. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent lowdosedaily cisplatin in locallyadvancedsquamouscellcarcinomaof thehead and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
10. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350: 1937-44.
11. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Berqerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
12. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C. Neck disease and distant metastases. Oral Oncol 2003;39:207-12.
13. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8.
14. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
15. Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, Miyamoto M, et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006;28:1375-84.
16. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer- testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
17. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996;47:93-101.
18. Ohmori M, Yasunaga S, Maehara Y, Sugimachi K, Sasazuki T. DNA typing of HLA class I (HLA-A) and class II genes (HLA-DR, -DQ and -DP) in Japanese patients with gastric cancer. Tissue Antigens 1997;50:277-82.
19. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012;10:141-9.
20. CLIA.; Available from https://www.cms.gov/CLIA/05-CLIA-Brochures.asp.
21. ICH.; Available from http://www.ich.org/products/guidelines.html.
22. Vormorken JB, Psyrri A, Mesia R, Peyrade F, Beier F, de Blas B, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014:25:801-7.
23. Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2014;25:2101-15.
24. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Impact study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
25. Weber JS, O'Day S, UrbaW, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-6.
26. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
27. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-94.
28. Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, et al. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets 2011;11:85-102.
29. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 2012;72:834-45.
30. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanomaassociated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011;29:2924-32.
31. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253: 328-35.
32. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8 T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}- type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.
33. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011;10:591-600.
34. Vikesaa J, Hansen TV, Jùnson L, Borup R, Wewer UM, Christiansen J, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006;25:1456-68.
35. deCarcer G, Perez de Castro I, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007;14:969-85.
36. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54.
37. Germeau C, MaW, Schiavetti F, Lurquin C, Henry E, Vigneron N, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201: 241-8.
38. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologicmonitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunother 2002;25: 97-138.
39. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 2011;17: 3064-76.
40. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, et al. SITC/iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools - A compass in the land of biomarker discovery. J Transl Med 2011;9:155.
41. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18: 3686-96.
42. Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, et al. Identification of promiscuous KIF20A long peptides bearing both CD4 and CD8 T-cell epitopes: KIF20A-specific CD4 T-cell immunity in patients with malignant tumor. Clin Cancer Res 2013;19: 4508-20.
43. Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, et al. Identification of CDCA1-derived long peptides bearing both CD4 and CD8 T-cell epitopes: CDCA1-specific CD4 T-cell immunity in cancer patients. Int J Cancer 2013;134:352-66.
44. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8 T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72.